Prenetics Global (NASDAQ:PRE) Posts Quarterly Earnings Results

Prenetics Global (NASDAQ:PRE) released its earnings results on Monday. The company reported ($0.41) earnings per share for the quarter, Zacks reports. Prenetics Global had a negative return on equity of 31.05% and a negative net margin of 87.92%. Prenetics Global updated its FY 2025 guidance to EPS.

Prenetics Global Price Performance

Shares of Prenetics Global stock opened at $12.42 on Monday. Prenetics Global has a 1-year low of $3.09 and a 1-year high of $17.99. The stock has a market cap of $209.05 million, a P/E ratio of -5.01 and a beta of 0.35. The stock’s 50 day simple moving average is $12.71 and its 200-day simple moving average is $9.43.

Analyst Ratings Changes

A number of research analysts have issued reports on PRE shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a report on Wednesday, October 8th. Cantor Fitzgerald raised their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Prenetics Global currently has an average rating of “Hold” and a consensus price target of $32.00.

Institutional Trading of Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. JPMorgan Chase & Co. acquired a new stake in Prenetics Global Limited (NASDAQ:PRE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,900 shares of the company’s stock, valued at approximately $65,000. 25.01% of the stock is currently owned by institutional investors.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.